Coherus Oncology Reports Third Quarter 2026 Financial Results and Announces Strategic Prioritization Plan

On November 9, 2026 Coherus Oncology, Inc. (Nasdaq: CHRS) reported financial results for the third quarter 2026 and provided an overview of recent business highlights.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The strategic prioritization of esophageal cancer as our best-in-disease focus for tagmokitug, together with the Transition Services Agreement wind-down and the toripalimab process transfer completion, provides an ideal opportunity to right-size the organization and deliver financial benefits that flow directly from this prioritization," said Denny Lanfear, Chief Executive Officer of Coherus Oncology. "Over the next four or five quarters we will remain intensely focused on growing LOQTORZI market share in relation to chemo-only, an inferior therapeutic approach, and off-label IO, which has not demonstrated standard-of-care level of benefit for patients living with nasopharyngeal carcinoma. We believe this approach can provide a path to financial self-sufficiency."

"Esophageal cancers constitute difficult-to-treat tumors with significant unmet medical need. The compelling anti-tumor activity observed in both ESCC and EAC tumors suggests that Tregs are a critical driver of resistance. Importantly, we saw tagmokitug enhance PD-1’s activity, demonstrate activity in PD-L1 negative tumors, and rescue PD-1 refractory patients," said Rosh Dias, M.D., Chief Medical Officer of Coherus Oncology. "Our immediate next step is to align with the FDA on our plans to expand the signal observed in esophageal cancer, with an initial focus on the second-line setting. This represents the fastest path to market in this underserved patient population."

"The financial benefits of right-sizing the organization and reducing the scope of our forward-focused efforts provide substantial and durable benefits to our operating model," said Bryan McMichael, Chief Financial Officer of Coherus Oncology. "These benefits will be realized over the next two quarters, lowering our core cash burn by $6 million to $7 million quarterly, which in turn lowers the quarterly LOQTORZI revenues required to cover core burn to $25 million to $30 million, down from $30 million to $35 million, as previously guided."

RECENT BUSINESS HIGHLIGHTS

LOQTORZI (toripalimab-tpzi) Commercial Updates

● LOQTORZI revenue for Q3 2026 was $14.0 million, a 25% increase over $11.2 million in Q3 2025, and a 3% increase versus $13.6 million in Q2 2026.

● Demand continued to grow in the third quarter, driven by an increasing number of patients on therapy and increasing treatment duration.
● LOQTORZI remains the only FDA-approved and available treatment in the U.S. for recurrent, locally advanced or metastatic nasopharyngeal carcinoma (NPC). It is the only preferred Category 1 first-line treatment option recommended in combination with cisplatin and gemcitabine and the only preferred subsequent-line treatment recommended by the National Comprehensive Cancer Network (NCCN).

ADVANCEMENT OF INNOVATIVE, NEXT-GENERATION ONCOLOGY PIPELINE

Tagmokitug is a highly selective, cytolytic anti-CCR8 antibody designed to preferentially deplete CCR8-positive regulatory T cells (Tregs) in the tumor microenvironment, with the goal of overcoming immune resistance and enhancing antitumor immune responses. Tagmokitug is being evaluated in the TREGCHECK Phase 1b/2a clinical program in combination with toripalimab, with and without chemotherapy. As part of the strategic prioritization plan, Coherus will focus near-term tagmokitug development on esophageal cancer and deprioritize the other tagmokitug-toripalimab cohorts presented during our October 28, 2026, data release. The Company will continue ongoing first-line ESCC and second-line ESCC and EAC indications and pursue regulatory alignment on an expedited development path, initially focused on second-line esophageal cancer.

● Enrollment remains ongoing in the Phase 1b cohorts evaluating tagmokitug in combination with toripalimab with or without chemotherapy in first- and second-line ESCC. The second-line EAC patients were enrolled as part of the upper gastrointestinal adenocarcinoma cohort, which has completed accrual and remains in follow-up.

● The overall interim clinical activity across second-line ESCC and second-line EAC of 22 treated and 13 evaluable patients demonstrated a confirmed ORR of 33.3% and a CBR of 55.6%. Coherus plans to initiate a new study evaluating tagmokitug in combination with toripalimab in patients with second line esophageal cancer (EAC and ESCC), an area of high unmet medical need. The Company intends to align with the FDA on the design of the new study and the proposed 700 mg dose, with the objective of pursuing an expedited development path.

● The Company plans to go forward with the Phase 1b clinical study evaluating tagmokitug in combination with pasritamig, a T-cell engaging bispecific antibody, in patients with metastatic castration-resistant prostate cancer (mCRPC), which is expected to initiate in the fall of 2026.

Casdozokitug is a first-in-class IL-27 antagonistic antibody currently being evaluated in a Phase 2 study in patients with first-line unresectable hepatocellular carcinoma (uHCC) to assess treatment benefit, safety, and response biomarkers.

● Enrollment in the randomized Phase 2 trial of casdozokitug/toripalimab/bevacizumab in 1L uHCC is complete and the first data readout is expected in 1H 2027.

THIRD QUARTER 2026 FINANCIAL RESULTS

Net revenue from continuing operations was $14.3 million and $11.6 million during the three months ended September 30, 2026 and 2025, respectively, and $40.9 million and $29.4 million during the nine months ended September 30, 2026 and 2025, respectively. The increases were driven primarily by volume growth of LOQTORZI.

Cost of goods sold (COGS) from continuing operations was $4.1 million and $3.7 million during the three months ended September 30, 2026 and 2025, respectively, and $12.1 million and $9.8 million during the nine months ended September 30, 2026 and 2025, respectively. The increases were primarily due to volume growth of LOQTORZI.

Research and development (R&D) expenses from continuing operations were $22.6 million and $27.3 million for the three months ended September 30, 2026 and 2025, respectively, and $65.6 million and $77.9 million during the nine months ended September 30, 2026 and 2025, respectively. The decreases were primarily due to savings from reduced headcount, lower infrastructure costs, and lower clinical trial and R&D manufacturing costs.

Selling, general and administrative (SG&A) expenses from continuing operations were $21.2 million and $24.9 million during the three months ended September 30, 2026 and 2025, respectively, and $65.3 million and $77.0 million during the nine months ended September 30, 2026 and 2025, respectively. The decreases were driven primarily by lower headcount and decreased operating costs resulting from Coherus completing the exit from the biosimilar business in 2025.

Net loss from continuing operations for the third quarter of 2026 was $38.9 million, or $(0.25) per share on a diluted basis, compared to $44.5 million, or $(0.38) per share on a diluted basis, for the same period in 2025. Net loss for the nine months ended September 2026 was $109.2 million, or $(0.73) per share on a diluted basis, compared to $136.8 million, or $(1.18) per share on a diluted basis for the same period of 2025.

Non-GAAP net loss from continuing operations for the third quarter of 2026 was $31.2 million, or $(0.20) per share on a diluted basis, compared to $38.9 million, or $(0.33) per share for the same period in 2025. Non-GAAP net loss for the nine months ended September 2026 was $95.3 million, or $(0.64) per share on a diluted basis, compared to $118.8 million, or $(1.02) per share for the same period in 2025. See "Non-GAAP Financial Measures" below for a discussion on how Coherus calculates non-GAAP net loss from continuing operations and a reconciliation to the most directly comparable GAAP measures.

Cash, cash equivalents and marketable securities totaled $83.6 million as of September 30, 2026, compared to $172.1 million as of December 31, 2025. These balances were inclusive of Transition Services Agreement (TSA)-related collections that will be applied to associated TSA payables and accrued liabilities which totaled $19.6 million and $65.1 million as of September 30, 2026 and December 31, 2025, respectively.

Conference Call Information

When: Monday, November 9, 2026, starting at 5:00 p.m. Eastern Standard Time

To access the conference call, please pre-register through the following link to receive dial-in information and a personal PIN to access the live call: View Source

Webcast: View Source

A live and archived webcast will be available on the "Investors" section of the Coherus website at

View Source

Please dial in 15 minutes early to ensure a timely connection to the call.

(Press release, Coherus Oncology, NOV 9, 2026, View Source [SID1234674466])

Pelareorep Induces Coordinated Antiviral Immune Responses and Enhanced Antitumor Immunity in Multiple Myeloma Patients

On November 9, 2026 Oncolytics Biotech Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, reported translational data in heavily pretreated relapsed/refractory multiple myeloma patients, which will be presented at the 68th American Society of Hematology (ASH) (Free ASH Whitepaper) ("ASH") Annual Meeting and Exposition.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Title: Pelareorep induces innate and adaptive antiviral immune activation in relapsed/refractory multiple myeloma: Single-cell analysis from a Phase 1b/2 trial
Abstract Number: 2183
Presentation Type: Poster
Presentation Date: Saturday, December 12, 2026

Highlights from the abstract include:
•The Phase 1b/2 trial evaluated bortezomib ("BOR"), dexamethasone ("DEX"), and pembrolizumab ("Pemb") in Cohort 1 and pelareorep plus BOR, DEX, and Pemb in Cohort 2 in patients with relapsed/refractory multiple myeloma. Patients had a median of four prior lines of therapy, with a range between three and eleven.
•Myeloid cells demonstrated enhanced antigen-presenting activity, including increased CD80 expression and reduced FCGR2B expression, suggesting an improved ability to stimulate antitumor T cell responses.
•Multiple myeloma cells exhibited increased apoptotic and p53 signaling and reduced MYC pathway activity, indicating direct biological effects on tumor cells alongside immune activation.
•There were notable increases in populations of CD8 effector memory ("CD8 EM") T cells, as well as upregulation of genes linked to T cell activation, antiviral activity, and cytotoxic function.
•Patients who showed a clinical response to treatment displayed greater expansion of CD8 EM T cells, in addition to lower levels of CD8 T cell exhaustion and terminal differentiation compared to non-responders.

"These changes are consistent with pelareorep’s mechanism of action and ability to remodel the tumor microenvironment, specifically its ability to activate TLR3-mediated antiviral signaling," said Thomas Heineman, MD, PhD, Chief Medical Officer of Oncolytics. "These single-cell sequencing data provide evidence that pelareorep can enhance immunological activity within the tumor microenvironment, demonstrating its potential immunotherapeutic activity and supporting further evaluation in combination with other immune-based treatments."

About Pelareorep
Pelareorep is an intravenously delivered, systemically active, investigational immunotherapy with a dual mechanism of action that selectively replicates in tumor cells while activating both innate and adaptive anti-tumor immune responses, including the upregulation of key inflammatory cytokines resulting in the formation of tertiary lymphoid structures and the expansion of tumor-infiltrating lymphocytes. It has been administered to over 1,200 patients, and clinical studies have demonstrated pelareorep’s potential to enhance the activity of checkpoint inhibitors and other anti-cancer therapies across multiple solid tumor types.

(Press release, Oncolytics Biotech, NOV 9, 2026, View Source [SID1234674482])

Myosin Therapeutics to Attend Society for Neuro-Oncology 2026 Annual Meeting

On November 9, 2026 Myosin Therapeutics reported that Dr. Courtney Miller (CEO) and Dr. Karen Smith (CMO) will attend the 31st Annual Meeting of the Society for Neuro-Oncology (SNO), taking place November 12–15, 2026, in Philadelphia, Pennsylvania. During the conference, they will meet with current clinical investigators and potential development partners to discuss progress in the company’s ongoing Phase 1/2 STAR-GBM clinical trial of MT-125, as well as preparations for transition into the Phase 2 portion in early 2027 and additional clinical indications later that year.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The NCI-supported STAR-GBM trial (NCT07185880), conducted at Mayo Clinic sites in Florida, Arizona and Minnesota, is evaluating MT-125 in patients with newly diagnosed, MGMT unmethylated glioblastoma (GBM). The study is progressing ahead of schedule through its Phase 1 dose escalation stage. The Phase 2 expansion will further evaluate MT-125 in additional treatment regimens, including oral maintenance therapy and a synergistic combination treatment.

"With STAR-GBM progressing toward its next phase of clinical development, SNO provides an important opportunity to engage directly with the investigators and the neuro-oncology community who are helping advance this novel approach to treating glioblastoma," said Courtney Miller, PhD, Chief Executive Officer of Myosin Therapeutics. "Our focus at SNO is on solidifying the clinical and strategic relationships that will ensure the next stage of development is successful."

Myosin Therapeutics is advancing MT-125, a first-in-class non-muscle myosin inhibitor designed to disrupt fundamental mechanical dependencies of cancer cells, leading to tumor cell death. Unlike conventional approaches that target processes such as molecular signaling pathways, MT-125 targets the physical machinery required for cancer cells to grow, divide, invade, metastasize, repair themselves, and survive. MT-125 has received FDA Orphan Drug Designation for malignant gliomas and FDA Fast Track Designation for GBM, and the company’s science is supported by two peer-reviewed publications in Cell.

Beyond GBM, Myosin is advancing a broader oncology pipeline focused on aggressive, treatment-resistant cancers. Preclinical studies have demonstrated the potential of MT-125 in solid and hematologic cancers, supporting the company’s strategy to develop MT-125 as a pan-oncology therapeutic. Myosin is planning to initiate clinical development in two additional cancers in 2027 while continuing preclinical and translational activities with other company assets.

(Press release, Myosin Therapeutics, NOV 9, 2026, View Source [SID1234674506])

Medicenna Presents ABILITY-1 Data at SITC 2026 Showing 40% ORR in Gastrointestinal Cancer Patients with Biomarker Enriched Tumors Resistant to Approved Therapies

On November 9, 2026 Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company developing Superkines for cancer and autoimmune disease, reported new clinical data from the Phase 1/2 ABILITY-1 study of MDNA11 presented during an oral session at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 2026 Annual Meeting.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation, titled "MDNA11 Demonstrates Clinical Activity as Monotherapy and in Combination with Pembrolizumab in Biomarker-Enriched Gastrointestinal Malignancies, Including ICI-Refractory Disease," was delivered by Professor Paolo Ascierto, MD, Director of Department of Skin Cancers, Cancer Immunotherapy and Development Therapeutics, National Cancer Institute IRCCS, Fondazione G. Pascale Naples, Italy.

As previously announced on November 4, 2026, the Company will host a KOL webinar on November 10, 2026 at 9:00 a.m. ET with Dr. Tawbi and Dr. Mansinho to discuss the results and their clinical implications. In addition, the webinar will include a presentation of new data from the ICI-resistant cutaneous melanoma and MSS endometrial cancer cohorts.

The SITC (Free SITC Whitepaper) presentation highlighted durable antitumor activity with MDNA11 alone and in combination with Merck’s (known as MSD outside of the US and Canada) anti-PD-1 therapy, KEYTRUDA (pembrolizumab), in patients with MSI-H or MSS TMB-H gastrointestinal (GI) cancers, including patients whose disease had progressed following prior ICI therapy.

Among 20 efficacy-evaluable patients with protocol-defined MSI-H or MSS TMB-H GI cancers, MDNA11 ± pembrolizumab achieved a 40% ORR (8/20) and 80% DCR (16/20). Responses were observed across multiple GI tumor types, including colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), cholangiocarcinoma and anal squamous cell carcinoma. The cohort was heavily pretreated, with a median of three prior systemic treatment lines, including adjuvant therapy (range 1-10); 65% had received prior ICI therapy, 45% had received at least four prior systemic treatment lines and 35% had active liver metastases at baseline.

"The 40% response rate observed in this 20-patient cohort of MSI-H or MSS/TMB-H gastrointestinal cancers is very promising, particularly because we are seeing responses in patients whose cancers have already progressed on immunotherapy and for whom effective treatment options are limited," stated Professor Paolo Ascierto, recipient of the 2026 SITC (Free SITC Whitepaper) Lifetime Achievement Award. "What stands out even more is the activity of MDNA11 monotherapy in patients with active liver metastases – a population that is difficult to treat and typically responds poorly to checkpoint inhibitors."

"The ABILITY-1 data presented at SITC (Free SITC Whitepaper) strengthens our conviction that MDNA11 can address a meaningful unmet need after checkpoint inhibitor failure in many different cancers," said Fahar Merchant, PhD, President and Chief Executive Officer of Medicenna. "We are particularly encouraged by the single-agent activity of MDNA11 in ICI-refractory GI cancers and the durability of these responses across multiple tumor types. Results from the melanoma and endometrial cancer cohorts, all refractory to immune checkpoint inhibitors, are similarly promising, positioning MDNA11 for potential registrational studies as we strengthen evidence to confirm durability of tumor control."

Key Findings in MSI-H/TMB-H Gastrointestinal Cancers

Combined cohort: 40% ORR (8/20) and 80% DCR (16/20); 5/8 responses were confirmed; ORR includes unconfirmed and ongoing responses.
Median duration of response was not reached with responses ongoing
MDNA11 monotherapy: 36% ORR (4/11) and 82% DCR (9/11).
MDNA11 + pembrolizumab: 44% ORR (4/9) and 78% DCR (7/9).ICI-refractory subset: 31% ORR (4/13), including 33% ORR (3/9 with MDNA11 monotherapy and 25% ORR (1/4) with MDNA11 + pembrolizumab.
Tumor regression was observed in 55% of evaluable patients (11/20).
Published post-ICI datasets in MSI-H/dMMR GI cancers have reported limited activity with available salvage approaches, including ORRs of approximately 11% with ICI rechallenge and approximately 12-13% with chemotherapy ± targeted therapy. Emerging salvage programs have reported ORRs in the approximately 7-22% range. These cross-trial comparisons are descriptive; patient populations, prior treatment exposure and response assessment differ across studies.

Single-Agent Activity in Patients with Liver Metastases

Liver metastases are associated with lower response rates and shorter progression-free survival following checkpoint inhibition in MSI-H/dMMR GI cancers. In ABILITY-1, MDNA11 showed single-agent activity in patients with active liver metastases:

All 4 evaluable MSI-H GI patients with measurable liver target lesions treated with MDNA11 monotherapy experienced regression of their liver lesions.
All 8 measurable hepatic target lesions (100%) regressed in patients with PDAC, CRC and cholangiocarcinoma
"The activity observed in patients whose cancers had already progressed on checkpoint therapy is clinically important, particularly the consistent regression of active liver lesions with MDNA11 monotherapy," said André Mansinho, MD, a principal investigator in the ABILITY-1 study and Director of Clinical Research at START Lisbon. "These patients often have limited effective treatment options, and liver metastases are associated with poorer outcomes even with checkpoint inhibition. The durability and breadth of activity suggests differential activity likely driven by the unique beta-enhanced design and albumin directed localization supporting the potential of MDNA11 to address unmet needs in cancer immunotherapy."

Clinical Activity in ICI-Resistant Cutaneous Melanoma and MSS Endometrial Cancer

ABILITY-1 also demonstrated durable activity with MDNA11 alone and in combination with pembrolizumab in heavily pretreated, Stage IV cutaneous melanoma. In the protocol defined expansion cohorts (N=18), 100% had Stage IV disease, 90% had prior exposure to both PD-1 and CTLA-4 therapy, and 30% had liver metastases.

In patients with secondary ICI resistance treated with MDNA11 monotherapy (n=10), ORR was 30% and DCR was 60%.
In patients with primary ICI resistance treated with MDNA11 + pembrolizumab (n=8), ORR was 38% and DCR was 38%.
MDNA11 plus pembrolizumab also showed efficacy signals in MSS endometrial cancer

In an expansion cohort comprising patients with secondary resistance to prior immune checkpoint inhibitor therapy (including multiple patients who had progressed following prior pembrolizumab plus lenvatinib), MDNA11 in combination with pembrolizumab achieved a confirmed objective response rate of 28.6% (2/7).
Additional data on melanoma and endometrial cancers will be shared during the KOL event.

Manageable Safety Profile

Across the pooled monotherapy and combination cohorts of the ABILITY-1 safety population (N=69 monotherapy; N=73 combination ), MDNA11 continued to demonstrate a manageable safety profile:

No dose-limiting toxicities were observed through 120 µg/kg.
More than 90% of treatment-related adverse events (TRAEs) were Grade 1 or Grade 2 and were predominantly transient, with a median duration of one to two days.
Approximately 65% of ≥ Grade 3 TRAEs were laboratory abnormalities, mostly asymptomatic.
Grade 4 TRAE were exceedingly rare, comprising 0.3% of all TRAE events in both treatment groups, and all but one were asymptomatic laboratory abnormalities.
One transient Grade 4 cytokine release syndrome event occurred in a patient with baseline low blood pressure and resolved within four days.
No Grade 5 treatment-related adverse events were reported.
No new safety signals were observed with the addition of pembrolizumab.
Treatment related dose reductions in monotherapy and combination were 2.9% and 5.5%, respectively. Treatment related permanent discontinuation were 0% and 4% in the monotherapy and combination arms, respectively.
KEYTRUDA is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

KOL Event

Medicenna will host a KOL event on November 10, 2026 from 9:00 to 10:00 a.m. ET featuring Hussein A. Tawbi, MD, PhD, Professor of Melanoma Medical Oncology and Director of Personalized Cancer Therapy at The University of Texas MD Anderson Cancer Center, and André Mansinho, MD, MSc, Director of Clinical Research at START Lisbon, to discuss the SITC (Free SITC Whitepaper) data, the new melanoma and endometrial cohort data, and the clinical development potential for MDNA11. To register, visit View Source

About MDNA11 and the ABILITY-1 Study

MDNA11 is an investigational, long-acting IL-2 Superkine engineered to preferentially activate and expand cancer-fighting CD8+ T cells and natural killer cells, with minimal stimulation of immunosuppressive regulatory T cells.

ABILITY-1 (NCT05086692) is an open-label, multicenter Phase 1/2 dose-escalation and expansion study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of MDNA11 alone and in combination with pembrolizumab in patients with advanced solid tumors. The study is being conducted in collaboration with Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

(Press release, Medicenna Therapeutics, NOV 9, 2026, View Source [SID1234674522])

Compugen Reports Third Quarter 2026 Results

On November 9, 2026 Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI, reported financial results for the third quarter of 2026 and provided a corporate update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"During the third quarter, we continued to advance COM701 and GS-0321 in the clinic, as well as build the next generation of our pipeline," said Eran Ophir, Ph.D., President and Chief Executive Officer of Compugen. "MAIA-ovarian is now fully enrolled, and we remain on track to report results by the end of the first quarter of 2027.We are also excited to see partner AstraZeneca continue to progress rilvegostomig, with Phase 3 high-level trial results from ARTEMIDE-Biliary01 anticipated in the second half of 2027. In addition, we introduced UnigenX, which expands our discovery capabilities into novel tumor-associated antigens, that could enable specific tumor targeting of potent therapeutic modalities such as T cell engagers. With cash runway expected into 2029, we believe we are well positioned to execute on our strategy and look forward to 2027, which we expect to be a data-rich year."

COM701

Compugen has completed enrollment in its MAIA-ovarian, its global, randomized, placebo-controlled adaptive platform trial evaluating COM701, a potential first-in-class anti-PVRIG antibody, as maintenance monotherapy in patients with second- and third-line relapsed platinum-sensitive ovarian cancer. The Company remains on track to report results by the end of the first quarter of 2027

The blinded trial enrolled 62 patients randomized two to one to receive either COM701 or placebo. MAIA-ovarian was designed to evaluate COM701 in a setting with no approved maintenance treatment option and significant unmet need.

At Compugen’s October 5, 2026, virtual key opinion leader event, Dr. Yeku of Harvard Medical School and Massachusetts General Hospital discussed the importance of extending the platinum-free interval in patients with relapsed platinum-sensitive ovarian cancer, the limitations of currently available maintenance options and the need to balance efficacy, tolerability and treatment sequencing.

In evaluating the MAIA-ovarian trial, Compugen intends to consider the totality of the data, including the magnitude and durability of separation between the COM701 and placebo arms and the proportion of patients remaining progression-free at six months. COM701 has the potential to serve as an important maintenance option for patients with relapsed platinum sensitive ovarian cancer who currently have very limited therapeutic alternatives.

Rilvegostomig

Rilvegostomig is an AstraZeneca-owned PD-1/TIGIT bispecific antibody whose TIGIT component is derived from Compugen’s COM902. Compugen is eligible to receive up to $195 million in additional regulatory and commercial milestone payments, as well as up to mid-single- digit tiered royalties on future sales, under its license agreement with AstraZeneca.

In September 2026, AstraZeneca reported the first overall survival data from the Phase 2 ARTEMIDE-01 trial in first-line, checkpoint inhibitor- and chemotherapy-naïve patients with PD-L1-positive non-small cell lung cancer. Median overall survival compared favorably with historical controls.

The Phase 3 high-level results from the clinical trial ARTEMIDE-Biliary01 studying rilvegostomig are now anticipated in the second half of 2027. ARTEMIDE-Biliary01 is assessing rilvegostomig plus investigator’s choice of chemotherapy compared to chemotherapy only as adjuvant treatment in 760 participants with biliary tract cancer who are at risk of recurrence after resection with curative intent. Rilvegostomig is being evaluated in 12 ongoing Phase 3 trials across indications including non-small cell lung cancer, biliary tract cancer and gastric cancer.

GS-0321

GS-0321, formerly known as COM503, is a potential first-in-class anti-IL-18 binding protein antibody licensed to Gilead. The program is designed to harness cytokine biology for the treatment of cancer while potentially overcoming limitations associated with direct cytokine administration.

The ongoing Phase 1 dose-escalation trial is continuing to advance.

Compugen has received gross payments totaling $90 million from Gilead under the license agreement and is eligible to receive up to $758 million in additional milestone payments, plus tiered royalties ranging from single digits to low double digits.

Early Pipeline

Unigen is Compugen’s AI-powered discovery engine for identifying novel immuno-oncology drug targets by connecting computational prediction, biological validation and clinical learning. Unigen has enabled the discovery of TIGIT, PVRIG and IL-18BP as drug targets, which have all progressed to clinical stage.

At its October 5, 2026, investor event, Compugen introduced UnigenX, a strategic expansion into targeted immune activation modalities such as T cell engagers, which can identify single targets and target pairs. Compugen intends to apply UnigenX to discover novel tumor-associated antigens that could enable more selective immune targeting of tumor cells.

This expanded capability is intended to support the next generation of Compugen’s early-stage pipeline.

Third Quarter 2026 Financial Highlights

· Cash: As of September 30, 2026, Compugen had approximately $117.5 million in cash, cash equivalents, short-term bank deposits and investments in marketable securities. Compugen expects its cash and cash-related balances to be sufficient to fund its operating plans into 2029. This does not include any additional cash inflows.

· Revenues for the third quarter of 2026 were approximately $3.8 million, compared with approximately $1.9 million for the comparable period in 2025. Revenues in the third quarters of 2026 and 2025 reflect the recognition of portions of both the upfront payment and the investigational new drug milestone payment under the license agreement with Gilead.

· Research and development expenses were approximately $5.8 million for each of the third quarters of 2026 and 2025.

· General and administrative expenses for the third quarter of 2026 were approximately $2.3 million, compared with approximately $2.2 million in the third quarter of 2025.

· Net loss for the third quarter of 2026 was approximately $5.8 million, or $0.06 per basic and diluted share, compared with a net loss of approximately $7.0 million, or $0.07 per basic and diluted share, in the third quarter of 2025.

Conference Call and Webcast Information

The Company will hold a conference call today, November 9, 2026, at 8:30 AM ET to review its third quarter 2026 results. To access the conference call by telephone, please dial 1-866-744-5399 from the United States, or +972-3-918-0644 internationally. The call will also be available via live webcast through Compugen’s website, located at the following link. Following the live audio webcast, a replay will be available on the Company’s website.

(Press release, Compugen, NOV 9, 2026, View Source [SID1234674467])